What is Noema Pharma?
Noema Pharma operates at the intersection of advanced neuroscience and drug development. The company is currently advancing a diverse portfolio of therapeutics targeting complex conditions, including seizures associated with Tuberous Sclerosis Complex, pain management in Trigeminal Neuralgia, Tourette syndrome, and CNS-mediated symptoms of menopause. By focusing on high-impact, first-in-disease assets, Noema Pharma has established itself as a critical player in the biotech ecosystem.
The company's operational strategy is supported by a consortium of top-tier venture capital firms, which provide not only the necessary financial resources but also deep scientific and business expertise. This institutional backing is essential for navigating the rigorous demands of Phase 2 clinical trials and the broader regulatory landscape, ensuring that Noema remains at the forefront of medical innovation.
How much funding has Noema Pharma raised?
Noema Pharma has raised a total of $206M across 2 funding rounds:
Series A
$59M
Series B
$147M
Series A (2020): $59M with participation from Polaris Partners and Sofinnova Partners
Series B (2024): $147M led by Sofinnova Partners, EQT Life Sciences, Forbion, Jeito, and Polaris Partners
Key Investors in Noema Pharma
Sofinnova Partners
A leading European venture capital firm in life sciences that acts as a hands-on company builder, supporting transformative innovations from seed to later-stage development.
Forbion
A global life sciences venture capital firm with a strong track record of guiding biotech and biopharmaceutical companies through complex clinical development stages.
Jeito Capital
A global investment company focused on accelerating the growth of ground-breaking medical innovations through a patient-benefit driven approach.
What's next for Noema Pharma?
With the successful closure of its latest funding round, Noema Pharma is poised to enter a critical phase of its corporate lifecycle. The influx of capital will likely be directed toward the continued execution of its active clinical trials and the potential expansion of its therapeutic pipeline. As the company approaches key data readouts, the focus will shift toward validating its clinical hypotheses and preparing for subsequent regulatory milestones.
Strategic priorities for the coming quarters include strengthening its internal research capabilities and potentially exploring partnerships that could enhance the commercialization pathway for its lead candidates. By maintaining its commitment to rigorous scientific inquiry and leveraging the support of its seasoned investor base, Noema Pharma is strategically aligned to address some of the most challenging conditions in modern neurology.
